Picture of Hanmi Pharm logo

128940 — Hanmi Pharm News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Sanofi sees strong profit growth from 2018, to cut costs (updated)

(Adds details) 
    PARIS, Nov 6 (Reuters) - Sanofi  SASY.PA  said on Friday 
that investment in products to compensate for declining diabetes 
sales and cost cuts would prevent significant profit growth in 
the next two years. 
    Earnings per share will, however, grow faster than sales at 
constant exchange rates from 2018, by which time it plans to 
have taken out some 1.5 billion euros ($1.6 billion) of costs, 
the French drugmaker said. 
    Sanofi also said ahead of a presentation of its five-year 
strategic plan to investors in Paris that it would raise annual 
research and development spending to 6 billion euros at constant 
exchange rates by 2020. This compares with 4.8 billion in 2014. 
    "As a result of investments in launches, headwinds in 
diabetes and the phasing of cost savings, Sanofi does not expect 
to show any meaningful bottom-line growth over 2016-2017," the 
company said in a statement. 
    "Beginning in 2018, however, Sanofi expects to grow business 
earnings per share faster than sales, reflecting its improved 
sales mix and the full capture of cost efficiencies." 
    Aiming to remain a diversified healthcare company while many 
competitors such as Switzerland's Roche  ROG.VX  have chosen to 
specialise in recent years, Sanofi said the savings would come 
from a reorganisation announced in July, due to be effective 
next year, as well as from a "reshape" of its plant network. 
    Sanofi said growth would be driven by 18 product launches 
scheduled for the next five years. 
    Among these, six key launches such as Toujeo, a 
next-generation insulin launched at the end of March in the 
United States to follow patent-expiring blockbuster Lantus, and 
anti-cholesterol Praluent, are expected to generate aggregate 
peak sales of between 12 billion euros and 14 billion by 2025. 
    In a separate announcement, the company said it had entered 
in a licence agreement in diabetes with U.S.-based Lexicon 
Pharmaceuticals  LXRX.O , following a deal with Korea's Hanmi 
Pharmaceutical  128940.KS  on Thursday.  ID:nFWN13009A  
 ID:nL8N1303GH  
    Sanofi surprised investors last week when it said revenue in 
its diabetes division would keep falling until 2018, due to 
growing competition, especially in the United States. 
 ID:nL8N12T0VP  
    The group said it was seeking "external opportunities",  
citing possible bolt-on acquisitions in consumer healthcare, 
adding its balance sheet would also be used for maintaining a 
"progressive" growth in its dividend - shareholders were granted 
a dividend of 2.85 euros in 2014 - and "opportunistic share 
buybacks".  
    Sanofi said it was exploring options for its animal health 
division, Merial, as well as for its European generics business. 
    "All options will be considered for these businesses 
including retention," Sanofi said. 
 ($1 = 0.9192 euros) 
 
 (Reporting by Matthias Blamont, Noelle Mennella; Editing by 
James Regan and David Holmes) 
 ((matthias.blamont@thomsonreuters.com ; +33 1 4949 5054; 
Reuters Messaging: matthias.blamont.reuters.com@reuters.net)) 
 
Keywords: SANOFI STRATEGY/

Recent news on Hanmi Pharm

See all news